Drug Wastage Program

Policy Number: Fallon004

Effective Date: 4.25.25

Last Review Date: 4.7.25

Status: Current

Drug Wastage Program

Related Policies:

None

Description:

This policy establishes a procedure for therapeutically appropriate, and cost-effective dose optimization of certain weight-based or body surface area (BSA) based infused medications. It requires dose rounding (i.e. reduction) for infused drug products to the nearest lowest vial size if within 10% of the original prescribed dose. This effort seeks to reduce the potential for errors in drug administration and decrease drug wastage across all drug products noted below.

This medical policy will apply to the following drugs:

• J9264 Abraxane • J3262 Actemra IV • J0791 Adakveo • J9042 Adcetris • J9305 Alimta • Q5126 Alymsys • J1426 Amondys-45 • J0881 Aranesp • J9118 Asparlas • J9035 Avastin • Q5121 Avsola • J9999 Avzivi • J3590 Avtozma IV • J9032 Beleodaq • J0490 Benlysta IV • J9039 Blincyto	• J2796 Nplate • J3590 Nypozi • J9205 Onivyde • J0222 Onpattro • J0224 Oxlumo • J9259 Paclitaxel Albumin-Bound (American Regent) • J9177 Padcev • J0208 Pedmark • J9322 pemetrexed (Bluepoint) • J9297 pemetrexed (Sandoz) • J9314 pemetrexed (Teva) • J9323 pemetrexed ditromethamine (Hospira) • J9296 pemetrexed (Accord) • J9294 pemetrexed (Hospira)

• J9046 Bortezomib (Dr. Reddy's) • J9048 Bortezomib (Fresenius Kabi) • J9049 Bortezomib (Hospira) • J9051 Bortezomib (Maia) • J9064 Cabazitaxel (Sandoz) • J2786 Cinqair • J1448 Cosela • J9308 Cyramza • J9348 Danyelza • J9145 Darzalex • J9999 Datroway • J9063 Elahere • J9269 Elzonris • J9176 Empliciti • J9358 Enhertu • J9055 Erbitux • J1305 Evkeeza • J1428 Exondys-51 • J0641 Fusilev • J9331 Fyarro • J0223 Givlaari • J1447 Granix • J0599 Haegarda • J9179 Halaven • J9355 Herceptin • J9999 Hercessi • J9347 Imjudo • Q5103 Inflectra • J9198 Infugem • J9043 Jevtana • J9354 Kadcyla • J0642 Khapzory • J9047 Kyprolis • J0174 Leqembi • J3263 Loqtorzi • J9313 Lumoxiti • J9999 Lymphir • J9353 Margenza • J0888 Mircera • J9349 Monjuvi • Q5107 Mvasi • J1442 Neupogen • J9038 Niktimvo	• J9292 pemetrexed (Axtle; Avyxa) • J9309 Polivy • J9204 Poteligeo • J0885 Procrit/Epogen • J0896 Reblozyl • Q5125 Releuko • J1745 Remicade/unbranded infliximab • Q5104 Renflexis • Q5106 Retacrit • Q5123 Riabni • J9312 Rituxan • J0596 Ruconest • Q5119 Ruxience • J9021 Rylaze • J0870 Rytelo • J9227 Sarclisa • J1602 Simponi_ARIA • J2860 Sylvant • J3055 Talvey • J9022 Tecentriq • J9380 Tecvayli • J3241 Tepezza • J9273 Tivdak • J3590 toclizumab-anoh • Q5133 Tofidence • J9033 Treanda • J9317 Trodelvy • Q5115 Truxima • Q5135 Tyenne IV/SQ • J9381 Tzield • J9999 Unituxin • J9303 Vectibix • Q5129 Vegzelma • J1427 Viltepso • J1429 Vyondys-53 • J9999 Vyloy • J9228 Yervoy • J9352 Yondelis • J9400 Zaltrap • Q5101 Zarxio • J9223 Zepzelca • J9999 Ziihera • Q5118 Zirabev

• Q5110 Nivestym	• J9359 Zynlonta

Policy:

The requirements of the Fallon Drug Wastage Program may require a precertification/prior authorization via Prime Therapeutics These requirements are member-specific: please verify member eligibility and requirements through the Fallon Provider Portal: https://www.fchp.org/Providertools/Login/Login.aspx?ReturnUrl=%2fprovidertools%2fEligibility

The dose will be rounded down for infused drug products if within 10% of the originally prescribed dose unless the following ***medical necessity*** criteria are met:

A. Provider indicates the recommended dose reduction may result in a suboptimal outcome due to one of the following:

1. Member's age is less than 18 years of age
2. Member is partially responsive to the original prescribed dose
3. Member previously demonstrated a suboptimal response to a lower rounded down dose
4. Member has a history of rapidly fluctuating body weight (i.e., weight gain of at least 10% body weight in a one-month time period within the past 6 months)
5. Member is clinically unstable and at high risk for hospitalization if the requested medication produces a suboptimal response
6. Member is being treated for an oncology indication with a curative goal (i.e. adjuvant, neoadjuvant)
7. Member's laboratory values indicate that a dose reduction will result in a suboptimal response

II. All other reasons not referenced in this policy are ***not considered medically necessary*.**

Medicare Coverage:

The Fallon policy does not apply to Medicare Advantage Products.

Medicaid Coverage:

For members enrolled in Medicaid, Fallon applies the above medical policy.

Exchange Coverage:

For members enrolled in an Exchange program, Fallon applies the above medical policy.

References:

1. Fahrenbruch R, Kintzel P, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. American Society of Clinical Oncology. March 2018. Volume 14, Issue 3. Jop.ascopubs.org
2. Park JJ, Boutillier L, et al. Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center. Journal of Managed Care & Specialty Pharmacy. October 2018. Vol. 24, No. 10. www.jmcp.orgwww.jmcp.org opens a dialog window.
3. IPD Analytics. RxBrief: Oncology. Oncology Management: Dose Rounding and Weight-Based Dosing. September 2020.
4. Vandyke TH, Athmann PW, Ballmer CM, Kintzel PE. Cost avoidance from dose rounding biologic and cytotoxic antineoplastics. J Oncol Pharm Pract. 2017 Jul;23(5):379-383. doi: 10.1177/1078155216639756. Epub 2016 Mar 21. PMID: 27000279.
5. Dooley MJ, et al. Implications of dose rounding of chemotherapy to the nearest vial size. *Support Care Cancer*. 2004 Sep;12(9):653-6. doi: 10.1007/s00520-004-0606-5
6. Buckley, B. Dose Rounding A Hedge Against High Cancer Cost. *Clinical Oncology News*. September 9, 2020. https://www.clinicaloncology.com/Current-Practice/Article/05-20/Dose-Rounding-A-Hedge-Against-High-Cancer-Cost/59426
7. Canadian Agency for Drugs and Technologies in Health. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs. Published online November 2019. Accessed September 23, 2020. https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf

8. Bennett, C. Drug Costs: Putting Oncologists in the Driver's Seat. *OBR Journal*. July 2019, Vol. 11, Issue 7. https://obroncology.com/article/drug-costs-putting-oncologists-in-the-drivers-seat/

9. Smith SM. Targeting Oncology Medications for Dose Rounding. Pharmacy Purchasing & Products Magazine. November 2019, Vol 16, No 11. Page 26. https://www.pppmag.com/article/2474https://www.pppmag.com/article/2474 opens a dialog window

10. Francis SM, Heyliger A, Miyares MA, Viera M. Potential cost savings associated with dose rounding antineoplastic monoclonal agents. *Journal of Oncology Pharmacy Practice*. 2015;21(4):280-284. doi:10.1177/107815521453336910.1177/1078155214533369 opens a dialog window

11. Ibrahim N (2018) Global Initiative to Establish and Implement Dose Rounding Policy for Expensive Cancer Therapy. J Pharma Care. Health Sys 5: e147. doi:10.4172/2376-0419.1000e147. https://www.longdom.org/open-access/global-initiative-to-establish-and-implement-dose-rounding-policy-forexpensive-cancer-therapy-2376-0419-1000e147.pdf

---

Codes:

(The list of codes is not intended to be all-inclusive and is included below for informational purposes only. Inclusion or exclusion of a procedure, diagnosis, drug or device code(s) does not constitute or imply authorization, certification, approval, offer of coverage or guarantee of payment.)

CPT*

HCPCS

Revisions:

Drug	Change or Update	Effective Date
Aduhelm	**Removed due to manufacturer d/c**	**4.1.25**
J0870- Rytelo **J3590 Nypozi**	**Added 5 drugs for mDW**	**3.14.25**

J9999 Lymphir **J9999 Vyloy** **J9999 Ziihera**		
J3590 Avtozma IV **J3590 toclizumab-anoh** **J9999 Datroway**		**4.15.25**
J9038 Niktimvo		**4.25.25**